NCT06540222 Sustained Cord Circulation at Emergency Cesarean Section
| NCT ID | NCT06540222 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | Asphyxia Neonatorum |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,200 participants |
| Start Date | 2025-09-08 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,200 participants in total. It began in 2025-09-08 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate if sustained cord circulation during resuscitation improves outcomes for term neonates born by emergency Cesarean section. The main question it aims to answer is: Does sustained cord circulation reduce admission rates to neonatal care? Researchers will compare resuscitation with an uncut umblical cord to standard resuscitation practices to see if it provides better outcomes. Participants (term neonates born by emergency Cesarean section) will: Receive resuscitation with either sustained cord circulation or standard care Be monitored for admission to neonatal care and other predefined health outcomes
Eligibility Criteria
Inclusion Criteria: * Singleton neonate * Born alive * Gestational age ≥37 weeks * Born by emergency cesarean section, epidural/spinal anesthesia, where the pediatric/neonatal team has been called for to attend. Exclusion Criteria: * Major congenital malformation that may affect resuscitation or outcome measures. * Major genetic disorder that may affect resuscitation or outcome measures.
Contact & Investigator
Ola Andersson, MD PhD
PRINCIPAL INVESTIGATOR
Region Skåne, Lund University
Frequently Asked Questions
Who can join the NCT06540222 clinical trial?
This trial is open to participants of all sexes, aged 37 Weeks or older, up to 42 Weeks, studying Asphyxia Neonatorum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06540222 currently recruiting?
Yes, NCT06540222 is actively recruiting participants. Contact the research team at ola.andersson@med.lu.se for enrollment information.
Where is the NCT06540222 trial being conducted?
This trial is being conducted at Gothenburg, Sweden, Halmstad, Sweden, Linköping, Sweden, Lund, Sweden and 8 additional locations.
Who is sponsoring the NCT06540222 clinical trial?
NCT06540222 is sponsored by Region Skane. The principal investigator is Ola Andersson, MD PhD at Region Skåne, Lund University. The trial plans to enroll 2,200 participants.